Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Non-Current Liabilities (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Other Non-Current Liabilities readings, the most recent being $219.7 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 32.19% to $219.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $219.7 million, a 32.19% increase, with the full-year FY2025 number at $219.7 million, up 32.19% from a year prior.
  • Other Non-Current Liabilities hit $219.7 million in Q4 2025 for Neurocrine Biosciences, up from $195.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $219.7 million in Q4 2025 to a low of $8.3 million in Q3 2021.
  • Median Other Non-Current Liabilities over the past 5 years was $78.6 million (2023), compared with a mean of $92.8 million.
  • Biggest five-year swings in Other Non-Current Liabilities: fell 7.51% in 2022 and later soared 301.17% in 2023.
  • Neurocrine Biosciences' Other Non-Current Liabilities stood at $12.3 million in 2021, then surged by 141.46% to $29.7 million in 2022, then skyrocketed by 257.91% to $106.3 million in 2023, then skyrocketed by 56.35% to $166.2 million in 2024, then surged by 32.19% to $219.7 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $219.7 million (Q4 2025), $195.7 million (Q3 2025), and $210.1 million (Q2 2025) per Business Quant data.